SecProbe.io

CORRESP
1
filename1.htm

November 9, 2022

VIA EDGAR AND EMAIL

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

    Attn:

    Margaret Schwartz

    Joe McCann

    Christie Wong

    Mary Mast

    Re:
    Clearmind Medicine Inc.

Amendment No. 7 to Registration Statement on Form F-1

Filed November 4, 2022

File No. 333-265900

Dear Ms. Schwartz:

On behalf of Clearmind Medicine Inc. (the “Company”),
we are writing to submit the Company’s responses to the comments of the staff (the “Staff”) of the Division of
Corporation Finance of the Securities and Exchange Commission (the “Commission”) dated November 8, 2022, relating to
the above referenced Amendment No. 7 to Registration Statement on Form F-1 (File No. 333-265900) filed by the Company on November 2, 2022.

Concurrent with the submission of this letter,
the Company is filing via EDGAR Amendment No. 8 to the F-1 (“Amendment No. 8”), which reflects the Company’s
responses to the comments received by the Staff and certain updated information.

For ease of review, we have set forth below each
of the numbered comments of your letter and the Company’s responses thereto. Capitalized terms used herein but not defined herein
have the meanings given to such terms in Registration Statement.

Amendment No. 7 to Form F-1 filed on November 4, 2022

Cover page

    1.

    Please revise to clarify whether your offering is contingent
    upon final approval of your NASDAQ listing. Please ensure the disclosure is consistent with your underwriting agreement.

Response: In response to the Staff’s comment the Company has
revised its disclosure on the cover page to further clarify that it is a condition to the closing of the offering that the Company’s
common shares shall have been approved for listing on The Nasdaq Capital Market, which is consistent with the underwriting agreement.

Risk Factors, page 13

    2.

    We note recent instances of extreme stock
    price run-ups followed by rapid price declines and stock price volatility seemingly unrelated to company performance following a
    number of recent initial public offerings, particularly among companies with relatively smaller public floats. Revise to include
    a separate risk factor addressing the potential for rapid and substantial price volatility and any known factors particular to your
    offering that may add to this risk and discuss the risks to investors when investing in stock where the price is changing rapidly.
    Clearly state that such volatility, including any stock-run up, may be unrelated to your actual or expected operating performance
    and financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of your
    stock.

Response: In response to the Staff’s comment the Company has
added the additional risk factor disclosure on page 7 and page 63.

Dilution, page 73

    3.

    Please revise to exclude intangible assets from your historical
    and adjusted net tangible book value and per share information.

Response: In response to the Staff’s comment the Company
has revised its disclosures on page 73 and page 74.

Please contact me at (212) 801-9221 if
you have any questions or require any additional information in connection with this letter or the Company’s submission of its draft
Registration Statement on Form F-1.

    Sincerely,

    /s/ David Huberman

    cc: Adi-Zuloff Shani, Chief Executive Officer